[1]
Popper, H.H. Progression and metastasis of lung cancer. Cancer Metastasis Rev., 2016, 35(1), 75-91.
[2]
Yamanaka, R. Medical management of brain metastases from lung cancer. Oncol. Rep., 2009, 22(6), 1269-1276.
[3]
Li, Y.S.; Jiang, B.Y.; Yang, J.J.; Tu, H.Y.; Zhou, Q.; Guo, W.B.; Yan, H.H.; Wu, Y.L. Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J. Thorac. Oncol., 2016, 11(11), 1962-1969.
[4]
Wu, Y.L.; Zhou, C.; Cheng, Y.; Lu, S.; Chen, G.Y.; Huang, C.; Huang, Y.S.; Yan, H.H.; Ren, S.; Liu, Y.; Yang, J.J. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: A phase II study (CTONG-0803). Ann. Oncol., 2013, 24(4), 993-999.
[5]
Kobayashi, S.; Boggon, T.J.; Dayaram, T.; Janne, P.A.; Kocher, O.; Meyerson, M.; Johnson, B.E.; Eck, M.J.; Tenen, D.G.; Halmos, B. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N. Engl. J. Med., 2005, 352(8), 786-792.
[6]
Cross, D.A.; Ashton, S.E.; Ghiorghiu, S.; Eberlein, C.; Nebhan, C.A.; Spitzler, P.J.; Orme, J.P.; Finlay, M.R.; Ward, R.A.; Mellor, M.J.; Hughes, G.; Rahi, A.; Jacobs, V.N.; Red Brewer, M.; Ichihara, E.; Sun, J.; Jin, H.; Ballard, P.; Al-Kadhimi, K.; Rowlinson, R.; Klinowska, T.; Richmond, G.H.; Cantarini, M.; Kim, D.W.; Ranson, M.R.; Pao, W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov., 2014, 4(9), 1046-1061.
[7]
Ballard, P.; Yates, J.W.; Yang, Z.; Kim, D.W.; Yang, J.C.; Cantarini, M.; Pickup, K.; Jordan, A.; Hickey, M.; Grist, M.; Box, M.; Johnstrom, P.; Varnas, K.; Malmquist, J.; Thress, K.S.; Janne, P.A.; Cross, D. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin. Cancer Res., 2016, 22(20), 5130-5140.
[8]
Cordova, C.; Chi, A.S.; Chachoua, A.; Kondziolka, D.; Silverman, J.S.; Shepherd, T.M.; Jain, R.; Snuderl, M. Osimertinib dose escalation induces regression of progressive EGFR T790M-mutant leptomeningeal lung adenocarcinoma. J. Thorac. Oncol., 2017, 12(11), e188-e190.
[9]
Nanjo, S.; Ebi, H.; Arai, S.; Takeuchi, S.; Yamada, T.; Mochizuki, S.; Okada, Y.; Nakada, M.; Murakami, T.; Yano, S. High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. Oncotarget, 2016, 7(4), 3847-3856.
[10]
Mok, T.S.; Wu, Y.L.; Ahn, M.J.; Garassino, M.C.; Kim, H.R.; Ramalingam, S.S.; Shepherd, F.A.; He, Y.; Akamatsu, H.; Theelen, W.S.; Lee, C.K.; Sebastian, M.; Templeton, A.; Mann, H.; Marotti, M.; Ghiorghiu, S.; Papadimitrakopoulou, V.A.; Investigators, A. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med., 2017, 376(7), 629-640.
[11]
Planchard, D.; Brown, K.H.; Kim, D.W.; Kim, S.W.; Ohe, Y.; Felip, E.; Leese, P.; Cantarini, M.; Vishwanathan, K.; Janne, P.A.; Ranson, M.; Dickinson, P.A. Osimertinib western and asian clinical pharmacokinetics in patients and healthy volunteers: Implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother. Pharmacol., 2016, 77(4), 767-776.
[12]
Rood, J.J.M.; van Bussel, M.T.J.; Schellens, J.H.M.; Beijnen, J.H.; Sparidans, R.W. Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2016, 1031, 80-85.
[13]
Xiong, S.; Deng, Z.; Sun, P.; Mu, Y.; Xue, M. Development and validation of a rapid and sensitive LC-MS/MS method for the pharmacokinetic study of osimertinib in rats. J. AOAC Int., 2017, 100(6), 1771-1775.
[14]
De Mattos-Arruda, L.; Weigelt, B.; Cortes, J.; Won, H.H.; Ng, C.K.; Nuciforo, P.; Bidard, F.C.; Aura, C.; Saura, C.; Peg, V.; Piscuoglio, S.; Oliveira, M.; Smolders, Y.; Patel, P.; Norton, L.; Tabernero, J.; Berger, M.F.; Seoane, J.; Reis-Filho, J.S. Capturing intra-tumour genetic heterogeneity by de novo mutation profiling of circulating cell-free tumour DNA: A proof-of- principle. Ann. Oncol., 2014, 25(9), 1729-1735.
[15]
De Mattos-Arruda, L.; Mayor, R.; Ng, C.K.; Weigelt, B.; Martínez-Ricarte, F.; Torrejon, D.; Oliveira, M.; Arias, A.; Raventos, C.; Tang, J.; Guerini-Rocco, E.; Martínez-Sáez, E.; Lois, S.; Marín, O.; de la Cruz, X.; Piscuoglio, S.; Towers, R.; Vivancos, A.; Peg, V. Ramon, y. Cajal. S.; Carles, J.; Rodon, J.; González-Cao, M.; Tabernero, J.; Felip, E.; Sahuquillo, J.; Berger, M.F.; Cortes, J.; Reis-Filho, J.S.; Seoane, J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat. Commun., 2015, 6, 8839.
[16]
Pentsova, E.I.; Shah, R.H.; Tang, J.; Boire, A.; You, D.; Briggs, S.; Omuro, A.; Lin, X.; Fleisher, M.; Grommes, C.; Panageas, K.S.; Meng, F.; Selcuklu, S.D.; Ogilvie, S.; Distefano, N.; Shagabayeva, L.; Rosenblum, M.; DeAngelis, L.M.; Viale, A.; Mellinghoff, I.K.; Berger, M.F. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J. Clin. Oncol., 2016, 34(20), 2404-2415.
[18]
Yang, H.; Yang, X.; Zhang, Y.; Liu, X.; Deng, Q.; Zhao, M.; Xu, X.; He, J. Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure. Target. Oncol., 2015, 10(1), 135-140.
[19]
Zhao, J.; Chen, M.; Zhong, W.; Zhang, L.; Li, L.; Xiao, Y.; Nie, L.; Hu, P.; Wang, M. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin. Lung Cancer, 2013, 14(2), 188-193.
[20]
Grommes, C.; Oxnard, G.R.; Kris, M.G.; Miller, V.A.; Pao, W.; Holodny, A.I.; Clarke, J.L.; Lassman, A.B. ‘Pulsatile’ high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Onco., 2011, 13(12), 1364-1369.
[21]
Li, Y.S.; Jiang, B.Y.; Yang, J.J.; Zhang, X.C.; Zhang, Z.; Ye, J.Y.; Zhong, W.Z.; Tu, H.Y.; Chen, H.J.; Wang, Z.; Xu, C.R.; Wang, B.C.; Du, H.J.; Chuai, S.; Han-Zhang, H.; Su, J.; Zhou, Q.; Yang, X.N.; Guo, W.B.; Yan, H.H.; Liu, Y.H.; Yan, L.X.; Huang, B.; Zheng, M.M.; Wu, Y.L. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small cell lung cancer: A new medium of liquid biopsy. Ann. Oncol., 2018, 29(4), 945-952.
[22]
Lin, Y.; Wang, X.; Jin, H. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am. J. Cancer Res., 2014, 4(5), 411-435.
[23]
Turke, A.B.; Zejnullahu, K.; Wu, Y.L.; Song, Y.; Dias-Santagata, D.; Lifshits, E.; Toschi, L.; Rogers, A.; Mok, T.; Sequist, L.; Lindeman, N.I.; Murphy, C.; Akhavanfard, S.; Yeap, B.Y.; Xiao, Y.; Capelletti, M.; Iafrate, A.J.; Lee, C.; Christensen, J.G.; Engelman, J.A.; Jänne, P.A. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell, 2010, 17(1), 77-88.
[24]
Bean, J.; Brennan, C.; Shih, J.Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; Balak, M.; Chang, W.C.; Yu, C.J.; Gazdar, A.; Pass, H.; Rusch, V.; Gerald, W.; Huang, S.F.; Yang, P.C.; Miller, V.; Ladanyi, M.; Yang, C.H.; Pao, W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumours with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA, 2007, 104(52), 20932-20937.
[25]
Wullschleger, S.; Loewith, R.; Hall, M.N. TOR signaling in growth and metabolism. Cell, 2006, 124(3), 471-484.
[26]
Karachaliou, N.; Codony-Servat, J.; Teixidó, C.; Pilotto, S.; Drozdowskyj, A.; Codony-Servat, C.; Giménez-Capitán, A.; Molina-Vila, M.A.; Bertrán-Alamillo, J. Gervais. R.; Massuti, B.; Morán, T.; Majem, M.; Felip, E.; Carcereny, E.; García-Campelo, R.; Viteri, S.; González-Cao, M.; Morales-Espinosa, D.; Verlicchi, A.; Crisetti, E.; Chaib, I.; Santarpia, M.; Luis Ramírez, J.; Bosch-Barrera, J.; Felipe Cardona, A.; de, Marinis. F.; López-Vivanco, G.; Miguel Sánchez, J.; Vergnenegre, A.; Sánchez Hernández, J.J.; Sperduti, I.; Bria, E.; Rosell, R. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci. Rep., 2015, 5, 17499.
[27]
Fei, S.J.; Zhang, X.C.; Dong, S.; Cheng, H.; Zhang, Y.F.; Huang, L.; Zhou, H.Y.; Xie, Z.; Chen, Z.H.; Wu, Y.L. Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells. PLoS One, 2013, 8(7)e69104
[28]
Uemura, T.; Oguri, T.; Ozasa, H.; Takakuwa, O.; Miyazaki, M.; Maeno, K.; Sato, S.; Ueda, R. ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci., 2010, 101(11), 2404-2410.
[29]
Oguri, T.; Bessho, Y.; Achiwa, H.; Ozasa, H.; Maeno, K.; Maeda, H.; Sato, S.; Ueda, R. MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol. Cancer Ther., 2007, 6(1), 122-127.
